VTVT - vTv Therapeutics inks licensing deal for HPP971 shares up 11%

vTv Therapeutics (VTVT) gains 11% premarket after entering into a licensing agreement with Anteris Bio for worldwide rights to its novel Nrf2 activator compound, HPP971 to be developed as a new therapy for renal disease. Under the terms of agreement, vTv will receive an upfront payment of $2M and might be eligible for up to $151M in milestone payments, as well as low double-digit royalties in exchange for development and commercialization rights to the compound.In addition, vTv will receive a minority equity interest in Anteris Bio.

For further details see:

vTv Therapeutics inks licensing deal for HPP971, shares up 11%